Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YAEL RACHEL ELFASSY

Allopathic & Osteopathic Physicians Pediatrics

NPI
1598081002
CMS profile
253025
Location
SAVANNAH, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$31.57

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $31.57 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI PASTEUR INC. $31.57 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YAEL RACHEL ELFASSY

NPI 1598081002 · CMS profile ID 253025

Allopathic & Osteopathic Physicians / Pediatrics

SAVANNAH, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YAEL RACHEL ELFASSY, NPI 1598081002, CMS profile ID 253025. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). YAEL RACHEL ELFASSY, NPI 1598081002, CMS profile ID 253025. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
YAEL RACHEL ELFASSY, NPI 1598081002, CMS profile ID 253025, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $31.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI PASTEUR INC. $17.4208/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937307117 CMS
SANOFI PASTEUR INC. $14.1504/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937307105 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $31.57 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $908,633.80 124
PY2024 Principal investigator $942,634.71 86
PY2023 Recipient $511.38 1
PY2023 Principal investigator $550,439.29 47
PY2022 Principal investigator $196,273.44 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

86 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $840.00 12/31/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1100764217
Principal investigator 1 ABBVIE INC. $602.00 12/31/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100764219
Principal investigator 1 ABBVIE INC. $3,167.34 12/31/2024 Non-covered Recipient Entity
IRESEARCH SAVANNAH
M21-465 Vraylar Ph3 Autism Spectrum Patients (2000-301-009) No dispute reported 06/30/2026 1100766983
Principal investigator 1 ModernaTX, Inc. $12,381.00 12/23/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192108
Principal investigator 1 ABBVIE INC. $500.00 12/18/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of?CVL-231?(Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1100761709
Principal investigator 1 ABBVIE INC. $12,526.62 12/18/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of?CVL-231?(Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1100761711
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,509.47 12/13/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder No dispute reported 06/30/2026 1143156636
Principal investigator 1 SANOFI PASTEUR INC. $71,474.40 12/05/2024 Non-covered Recipient Entity
Cenexel Iresearch Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1128696764
Principal investigator 1 ABBVIE INC. $7,500.00 12/02/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of?CVL-231?(Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1100757355
Principal investigator 1 ModernaTX, Inc. $94,044.00 11/27/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192102
Principal investigator 1 ModernaTX, Inc. $1,873.80 11/22/2024 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147154067
Principal investigator 1 SANOFI PASTEUR INC. $10,000.00 11/22/2024 Non-covered Recipient Entity
Cenexel Iresearch Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1128696768
Principal investigator 1 SANOFI PASTEUR INC. $1,700.00 11/22/2024 Non-covered Recipient Entity
Cenexel Iresearch Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1128696770
Principal investigator 1 SANOFI US SERVICES INC. $1,504.78 11/22/2024 Non-covered Recipient Entity
Cenexel Iresearch Llc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128705149
Principal investigator 1 ABBVIE INC. $1,750.00 11/20/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of00FFCVL-23100FF(Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1100755965
Principal investigator 1 ABBVIE INC. $3,849.38 11/20/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of00FFCVL-23100FF(Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1100755967
Principal investigator 1 ModernaTX, Inc. $700.00 11/15/2024 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147154069
Principal investigator 1 ABBVIE INC. $1,500.00 11/01/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of00FFCVL-23100FF(Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1100751475
Principal investigator 1 Eli Lilly and Company $15,905.00 11/01/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137354516
Principal investigator 1 SANOFI US SERVICES INC. $8,802.82 10/25/2024 Non-covered Recipient Entity
Cenexel Iresearch Llc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128705151
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $500.00 10/24/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder No dispute reported 06/30/2026 1143139360
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $721.17 10/24/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder No dispute reported 06/30/2026 1143139364
Principal investigator 1 ModernaTX, Inc. $9,050.00 10/24/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147192096
Principal investigator 1 Corium, LLC $12,329.25 10/09/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1118400182
Principal investigator 1 ModernaTX, Inc. $931.50 10/01/2024 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147154063
Principal investigator 1 ModernaTX, Inc. $484.81 10/01/2024 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147154065
Principal investigator 1 ModernaTX, Inc. $2,550.00 09/13/2024 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147154061
Principal investigator 1 SANOFI US SERVICES INC. $400.00 09/13/2024 Non-covered Recipient Entity
Cenexel Iresearch Llc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730610
Principal investigator 1 ABBVIE INC. $4,768.20 09/04/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100741058
Principal investigator 1 SANOFI US SERVICES INC. $2,801.66 09/04/2024 Non-covered Recipient Entity
Cenexel Iresearch Llc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730520
Principal investigator 1 ModernaTX, Inc. $668.25 08/28/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147192082
Principal investigator 1 ModernaTX, Inc. $598.68 08/27/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192084
Principal investigator 1 Eli Lilly and Company $2,415.00 08/20/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137356058
Principal investigator 1 Corium, LLC $38,669.42 08/16/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Efficacy and Safety Study w/ Azstarys in Children With ADHD No dispute reported 06/30/2026 1118400022
Principal investigator 1 Corium, LLC $26,316.60 08/07/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1118400126
Principal investigator 1 PFIZER INC. $475.00 08/06/2024 Non-covered Recipient Entity
CenExel iResearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131032770
Principal investigator 1 ABBVIE INC. $6,075.00 08/02/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100734456
Principal investigator 1 SANOFI US SERVICES INC. $3,506.36 07/17/2024 Non-covered Recipient Entity
Cenexel Iresearch Llc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730518
Principal investigator 1 ModernaTX, Inc. $3,720.60 07/12/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147192064
Principal investigator 1 ABBVIE INC. $1,034.10 07/11/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100728746
Principal investigator 1 Corium, LLC $6,301.05 07/11/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1118400124
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,500.00 07/10/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder No dispute reported 06/30/2026 1143127311
Principal investigator 1 ABBVIE INC. $15,930.00 07/05/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100727598
Principal investigator 1 SANOFI US SERVICES INC. $2,458.35 07/03/2024 Non-covered Recipient Entity
Cenexel Iresearch Llc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730516
Principal investigator 1 PFIZER INC. $133,733.49 06/25/2024 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131066980
Principal investigator 1 ABBVIE INC. $521.10 06/12/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100723346
Principal investigator 1 ABBVIE INC. $449.55 06/12/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100723354
Principal investigator 1 ABBVIE INC. $2,160.00 06/12/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100723356
Principal investigator 1 ABBVIE INC. $31,708.80 06/06/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100722316
Principal investigator 1 Corium, LLC $14,958.00 06/04/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1118399982
Principal investigator 1 ModernaTX, Inc. $6,847.20 05/29/2024 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147154059
Principal investigator 1 Amgen Inc. $8,836.15 05/24/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Phase P3 Pediatric Study EM No dispute reported 06/30/2026 1096315459
Principal investigator 1 PFIZER INC. $4,250.04 05/24/2024 Non-covered Recipient Entity
CenExel iResearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131080389
Principal investigator 1 PFIZER INC. $7,114.25 05/24/2024 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131080395
Principal investigator 1 ABBVIE INC. $40,257.00 05/09/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100717616
Principal investigator 1 SANOFI US SERVICES INC. $10,000.00 05/08/2024 Non-covered Recipient Entity
Cenexel Iresearch Atlanta
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128711399
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 05/08/2024 Non-covered Recipient Entity
Cenexel Iresearch Atlanta
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128711401
Principal investigator 1 Corium, LLC $15,036.68 05/01/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Efficacy and Safety Study w/ Azstarys in Children With ADHD No dispute reported 06/30/2026 1118399932
Principal investigator 1 ModernaTX, Inc. $8,500.00 04/26/2024 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147154039
Principal investigator 1 ABBVIE INC. $313.20 04/25/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100714994
Principal investigator 1 ABBVIE INC. $1,890.00 04/25/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100715010
Principal investigator 1 ABBVIE INC. $1,012.50 04/25/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100715012
Principal investigator 1 Amgen Inc. $9,563.70 04/20/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Ph3 Pediatric CM Study No dispute reported 06/30/2026 1096315013
Principal investigator 1 ModernaTX, Inc. $2,718.90 04/10/2024 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147154041
Principal investigator 1 ModernaTX, Inc. $83.75 04/10/2024 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147154043
Principal investigator 1 ABBVIE INC. $20,563.20 04/04/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100711958
Principal investigator 1 ABBVIE INC. $432.00 03/28/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100710266
Principal investigator 1 ABBVIE INC. $1,653.75 03/28/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100710276
Principal investigator 1 ABBVIE INC. $1,350.00 03/28/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100710278
Principal investigator 1 ABBVIE INC. $1,732.05 03/28/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100710288
Principal investigator 1 ABBVIE INC. $745.20 03/28/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100710290
Principal investigator 1 ModernaTX, Inc. $10,811.00 03/28/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147192080
Principal investigator 1 ModernaTX, Inc. $1,927.80 03/21/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147192078
Principal investigator 1 ABBVIE INC. $1,854.00 03/14/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100708521
Principal investigator 1 ModernaTX, Inc. $14,511.15 03/08/2024 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147154025
Principal investigator 1 ABBVIE INC. $20,656.35 03/07/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100707444
Principal investigator 1 Corium, LLC $13,836.72 03/06/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Efficacy and Safety Study w/ Azstarys in Children With ADHD No dispute reported 06/30/2026 1118399850
Principal investigator 1 Corium, LLC $22,981.50 03/06/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1118399892
Principal investigator 1 ModernaTX, Inc. $2,412.15 02/09/2024 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147154021
Principal investigator 1 ABBVIE INC. $4,969.00 02/02/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1100702620
Principal investigator 1 Corium, LLC $30,550.89 02/01/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Efficacy and Safety Study w/ Azstarys in Children With ADHD No dispute reported 06/30/2026 1118399848
Principal investigator 1 PFIZER INC. $9,167.00 01/31/2024 Non-covered Recipient Entity
CenExel iResearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131108614
Principal investigator 1 ModernaTX, Inc. $66.24 01/10/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1147192054
Principal investigator 1 Amgen Inc. $8,047.76 01/09/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Ph3 Pediatric CM Study No dispute reported 06/30/2026 1096315015
Principal investigator 1 Amgen Inc. $9,547.03 01/09/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Phase P3 Pediatric Study EM No dispute reported 06/30/2026 1096315461
Principal investigator 1 Eli Lilly and Company $66,530.00 01/02/2024 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1137356060